2026年以来,国内药企在精神/神经(CNS)领域的新药研发收获颇丰。多款创新药物在精神分裂症、抑郁症、阿尔茨海默病等方向取得关键进展,既有 原料药 / 制剂上市,也有1 类新药临床获批,研发管线正日益丰富。近日,康弘药业申报的化学1类新药KHN707片获得国家药监局药品审评中心(CDE)临床试验批准,适应症为失眠症。这是一款康弘药业自主研发的口服小分子选择性食欲素受体(OX2R)拮抗剂,在临床前...
Source Link2026年以来,国内药企在精神/神经(CNS)领域的新药研发收获颇丰。多款创新药物在精神分裂症、抑郁症、阿尔茨海默病等方向取得关键进展,既有 原料药 / 制剂上市,也有1 类新药临床获批,研发管线正日益丰富。近日,康弘药业申报的化学1类新药KHN707片获得国家药监局药品审评中心(CDE)临床试验批准,适应症为失眠症。这是一款康弘药业自主研发的口服小分子选择性食欲素受体(OX2R)拮抗剂,在临床前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.